- Conditions
- Prostate Cancer
- Interventions
- Abemaciclib 150 MG by mouth twice daily, Androgen deprivation therapy (ADT), Radiation Therapy
- Drug · Radiation
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 9,512
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Prostate Cancer
- Interventions
- [68Ga]PSMA-PET/MRI or PET/CT
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Fussy Infant (Baby)
- Interventions
- Infant Formula - Partially hydrolyzed protein, Infant Formula - Intact protein
- Other
- Lead sponsor
- Mead Johnson Nutrition
- Industry
- Eligibility
- 15 Days to 75 Days
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Miramar, Florida • Sarasota, Florida + 7 more
- Conditions
- Gout
- Interventions
- Allopurinol, Naproxen 250 MG, Colchicine 0.6 mg, Colchicine 1.2 mg, Naproxen 500 Mg, Prednisone 40 mg
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 7
- States / cities
- South Birmingham, Alabama • Santa Monica, California • Boston, Massachusetts + 2 more
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
- Interventions
- NAV4694
- Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 48 more
- Conditions
- Heart Failure, Congestive, Ventricular Dysfunction, Cardiomyopathies
- Interventions
- Thoratec HeartMate II Left Ventricular Assist System (LVAS)
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 30 more
- Conditions
- Chest Pain
- Interventions
- Imipramine, Cognitive-behavior therapy
- Drug · Behavioral
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cystic Fibrosis
- Interventions
- Open-platform patient support system (PSS) app
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Interventions
- Surufatinib in combination with Gemcitabine
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 8 more
- Conditions
- HIV-1 Infection, H1N1, Influenza, Flu
- Interventions
- FluMist, Fluvirin, Fluzone
- Biological
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Network
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Tobacco Use Disorder
- Interventions
- Psilocybin, Niacin
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • New York, New York
- Conditions
- Iron Deficiency Anemia
- Interventions
- Ferumoxytol, Placebo
- Drug · Other
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 812 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 137
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 105 more
- Conditions
- Asthma
- Interventions
- MSTT1041A, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 37 more
- Conditions
- HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
- Interventions
- MM-111, Paclitaxel, Trastuzumab
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 16 more
- Conditions
- Mature B-Cell Non-Hodgkin Lymphoma
- Interventions
- Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin, Etoposide, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 6 Months to 30 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Oakland, California • Roseville, California + 6 more
- Conditions
- Pancreatic Cancer
- Interventions
- SM-88 used with MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, and 5-FU
- Drug
- Lead sponsor
- Tyme, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • Santa Monica, California + 13 more
- Conditions
- Acute HIV Infection
- Interventions
- VRC07-523LS, PGT121.414.LS, Placebo, ART
- Biological · Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 6 more
- Conditions
- Cystic Fibrosis
- Interventions
- LUM, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Months to 23 Months
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 21 more
- Conditions
- Stress, Anxiety, Mental Disorder, Distress-based Psychopathology
- Interventions
- Acceptance and commitment therapy
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 17,183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 303
- States / cities
- Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
- Device · Drug
- Lead sponsor
- NovoCure GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Fullerton, California + 34 more
- Conditions
- Cervical Cancer
- Interventions
- cisplatin, adjuvant therapy, conventional surgery, brachytherapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 43 more
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Fludarabine, Hydrocortisone Sodium Succinate, Imetelstat, Leucovorin Calcium, Lumbar Puncture, Methotrexate
- Procedure · Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 16 more
- Conditions
- Dermatomyositis
- Interventions
- PF-06823859 low, Placebo Arm, PF-06823859 high
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 17 more